Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study.
Do cortical lesions help us to distinguish MS from NMO?
Pitfalls of 3D FLAIR Brain Imaging: A Prospective Comparison with 2D FLAIR.
Expanding the Clinical Indications for Alpha-1-Antitrypsin Therapy.
Disease progression in chronic relapsing experimental allergic encephalomyelitis is associated with reduced inflammation-driven production of corticosterone.
Multiple sclerosis and the spinal cord.
Reversible blindness in bilateral optic neruritis associated with nasal flu vaccine.
Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis.
Riluzole enhances the anti-seizure action of conventional antiepileptic drugs against pentetrazole-induced convulsions in mice.
Pediatric Multiple Sclerosis.
Brain circuitry outside the synaptic cleft.
Changes in nociceptive sensitivity and object recognition in experimental autoimmune encephalomyelitis (EAE).
Origins and significance of astrogliosis in the multiple sclerosis model, MOG peptide EAE.
Oral BG-12 in multiple sclerosis.
Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
The behavior-analytic origins of constraint-induced movement therapy: an example of behavioral neurorehabilitation.
Exosomes as a potential novel therapeutic tools against neurodegenerative diseases.
Prognostic factors of acute partial transverse myelitis.
Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination.
Extracting quantitative measures from EAP: a small clinical study using BFOR.
Experimental RRMS Therapy to Be Tested in a Phase 2b Clinical Trial
Apolipoprotein E polymorphisms status in Iranian patients with multiple sclerosis.
Signaling and Regulatory Functions of Bioactive Sphingolipids as Therapeutic Targets in Multiple Sclerosis.
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Serial electrophysiological findings in Guillain-Barré syndrome not fulfilling AIDP or AMAN criteria.
Pages
« first
‹ previous
…
192
193
194
195
196
197
198
199
200
…
next ›
last »